In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trial Results

Summaries of Newsworthy Clinical Trial Results < Back to Main

Page Options

  • Print This Page
  • Email This Document

Search Trial Results

Leukemia Trial Results


Imatinib Added to Chemotherapy Keeps Disease in Check for Longer in Children with Rare Form of Acute Lymphoblastic Leukemia
(Posted: 11/30/2009) - The addition of the targeted drug imatinib to chemotherapy for children with an uncommon form of acute lymphoblastic leukemia (ALL) dramatically improved the length of time the disease remained in remission, according to the November 1, 2009, Journal of Clinical Oncology.

Young Adults with Acute Lymphoblastic Leukemia Do Well on Intensified Pediatric Chemotherapy Regimen
(Posted: 11/30/2009) - Adolescents and young adults with acute lymphoblastic leukemia lived longer when treated with an intensified multi-drug chemotherapy regimen that is used to treat younger children, according to the November 1, 2009, Journal of Clinical Oncology.

For Children with Leukemia, Radiation May Be Unnecessary
(Posted: 07/23/2009) - Children with the most common form of leukemia can safely forego radiation therapy to prevent relapse if they are treated with chemotherapy regimens tailored to their individual needs, according to the June 25, 2009, New England Journal of Medicine.

Donated Stem Cell Transplants Better than Self-transplants for Most Patients with AML
(Posted: 07/23/2009) - Evidence from a meta-analysis of prospective clinical trials supports the use of donated (or allograft) stem cell transplants to treat most individuals with acute myeloid leukemia, according to the June 10, 2009, Journal of the American Medical Association.

High Dose Chemotherapy Significantly Prolongs Survival for Patients with Acute Myeloid Leukemia
(Posted: 11/17/2008) - Preliminary results from a large, randomized clinical trial for patients ages 16 to 60 with previously untreated acute myeloid leukemia, a cancer of the blood and bone marrow, show that patients who received a high dose of a commercially available chemotherapy drug, daunorubicin, during initial therapy lived longer than patients who received a standard dose of the same drug.

< Previous  1 2 3 4  Next >